ilac-MRA

**SLOVENSKA
AKREDITACIJA**
SIST EN ISO/IEC 17025
LP-117
The results marked by # relate to
non-accredited activity

CERTIFICATE OF ANALYSIS No.: 2022-8011

CBD CRYSTALLINE
POWDER
CB99022063E

SAMPLE *

CBD CRYSTALLINE POWDER

Sample condition:	SUITABLE	Work order:	2022-106260	Sample received:	04/03/2022
Sample ID:	2209081	Analysis ID:	2022_052	Start of analysis:	04/03/2022
Sample type:	Crystal	Method ID:	PHL_RPC_12C	End of analysis:	07/03/2022
		Method SOP:	MET-002-03	Analyst:	Janez Gerdenc

* Information provided by the client.

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV - Cannabidivarin	0.313	0.056	
CBDA - Cannabidiolic acid	< LOQ	n/a	
CBGA - Cannabigerolic acid	< LOQ	n/a	
CBG - Cannabigerol	< LOQ	n/a	
CBD - Cannabidiol	99.5	5.0	
THCV - Tetrahydrocannabivarin	< LOQ	n/a	
CBN - Cannabinol	< LOQ	n/a	
CBC - Cannabichromene	< LOQ	n/a	
THC - Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
THCA - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
8-THC - Δ-8-Tetrahydrocannabinol	< LOQ [#]	n/a	
CBL - Cannabicyclol	< LOQ [#]	n/a	

Units and abbreviations: **% w/w** = weight percent, **< LOQ** = below the limit of quantitation (0.03 % w/w), **ND** = not detected, **n/a** = not available.

The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

07/03/2022

Approved by:

mag. Marko Dragan
Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar
Chief Technology Officer

End of Certificate